BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 27321184)

  • 1. Inhibition of the CRAF/prohibitin interaction reverses CRAF-dependent resistance to vemurafenib.
    Doudican NA; Orlow SJ
    Oncogene; 2017 Jan; 36(3):423-428. PubMed ID: 27321184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation.
    Su F; Bradley WD; Wang Q; Yang H; Xu L; Higgins B; Kolinsky K; Packman K; Kim MJ; Trunzer K; Lee RJ; Schostack K; Carter J; Albert T; Germer S; Rosinski J; Martin M; Simcox ME; Lestini B; Heimbrook D; Bollag G
    Cancer Res; 2012 Feb; 72(4):969-78. PubMed ID: 22205714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib.
    Graziani G; Artuso S; De Luca A; Muzi A; Rotili D; Scimeca M; Atzori MG; Ceci C; Mai A; Leonetti C; Levati L; Bonanno E; Tentori L; Caccuri AM
    Biochem Pharmacol; 2015 May; 95(1):16-27. PubMed ID: 25795251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.
    Trunzer K; Pavlick AC; Schuchter L; Gonzalez R; McArthur GA; Hutson TE; Moschos SJ; Flaherty KT; Kim KB; Weber JS; Hersey P; Long GV; Lawrence D; Ott PA; Amaravadi RK; Lewis KD; Puzanov I; Lo RS; Koehler A; Kockx M; Spleiss O; Schell-Steven A; Gilbert HN; Cockey L; Bollag G; Lee RJ; Joe AK; Sosman JA; Ribas A
    J Clin Oncol; 2013 May; 31(14):1767-74. PubMed ID: 23569304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SHOC2 and CRAF mediate ERK1/2 reactivation in mutant NRAS-mediated resistance to RAF inhibitor.
    Kaplan FM; Kugel CH; Dadpey N; Shao Y; Abel EV; Aplin AE
    J Biol Chem; 2012 Dec; 287(50):41797-807. PubMed ID: 23076151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting prohibitins with chemical ligands inhibits KRAS-mediated lung tumours.
    Yurugi H; Marini F; Weber C; David K; Zhao Q; Binder H; Désaubry L; Rajalingam K
    Oncogene; 2017 Aug; 36(33):4778-4789. PubMed ID: 28414306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. miR-7 reverses the resistance to BRAFi in melanoma by targeting EGFR/IGF-1R/CRAF and inhibiting the MAPK and PI3K/AKT signaling pathways.
    Sun X; Li J; Sun Y; Zhang Y; Dong L; Shen C; Yang L; Yang M; Li Y; Shen G; Tu Y; Tao J
    Oncotarget; 2016 Aug; 7(33):53558-53570. PubMed ID: 27448964
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prominent role of cyclic adenosine monophosphate signalling pathway in the sensitivity of (WT)BRAF/(WT)NRAS melanoma cells to vemurafenib.
    Krayem M; Journe F; Wiedig M; Morandini R; Sales F; Awada A; Ghanem G
    Eur J Cancer; 2014 May; 50(7):1310-20. PubMed ID: 24559688
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of Therapeutic Senescence in Vemurafenib-Resistant Melanoma by Extended Inhibition of CDK4/6.
    Yoshida A; Lee EK; Diehl JA
    Cancer Res; 2016 May; 76(10):2990-3002. PubMed ID: 26988987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma.
    Fofaria NM; Frederick DT; Sullivan RJ; Flaherty KT; Srivastava SK
    Oncotarget; 2015 Dec; 6(38):40535-56. PubMed ID: 26497853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Nexus Consisting of Beta-Catenin and Stat3 Attenuates BRAF Inhibitor Efficacy and Mediates Acquired Resistance to Vemurafenib.
    Sinnberg T; Makino E; Krueger MA; Velic A; Macek B; Rothbauer U; Groll N; Pötz O; Czemmel S; Niessner H; Meier F; Ikenberg K; Garbe C; Schittek B
    EBioMedicine; 2016 Jun; 8():132-149. PubMed ID: 27428425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The c-Jun/RHOB/AKT pathway confers resistance of BRAF-mutant melanoma cells to MAPK inhibitors.
    Delmas A; Cherier J; Pohorecka M; Medale-Giamarchi C; Meyer N; Casanova A; Sordet O; Lamant L; Savina A; Pradines A; Favre G
    Oncotarget; 2015 Jun; 6(17):15250-64. PubMed ID: 26098773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma.
    Montagut C; Sharma SV; Shioda T; McDermott U; Ulman M; Ulkus LE; Dias-Santagata D; Stubbs H; Lee DY; Singh A; Drew L; Haber DA; Settleman J
    Cancer Res; 2008 Jun; 68(12):4853-61. PubMed ID: 18559533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The natural anticancer compounds rocaglamides inhibit the Raf-MEK-ERK pathway by targeting prohibitin 1 and 2.
    Polier G; Neumann J; Thuaud F; Ribeiro N; Gelhaus C; Schmidt H; Giaisi M; Köhler R; Müller WW; Proksch P; Leippe M; Janssen O; Désaubry L; Krammer PH; Li-Weber M
    Chem Biol; 2012 Sep; 19(9):1093-104. PubMed ID: 22999878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting B-Raf inhibitor resistant melanoma with novel cell penetrating peptide disrupters of PDE8A - C-Raf.
    Blair CM; Walsh NM; Littman BH; Marcoux FW; Baillie GS
    BMC Cancer; 2019 Mar; 19(1):266. PubMed ID: 30909892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Novel Class of Small Molecule Compounds that Inhibit Hepatitis C Virus Infection by Targeting the Prohibitin-CRaf Pathway.
    Liu S; Wang W; Brown LE; Qiu C; Lajkiewicz N; Zhao T; Zhou J; Porco JA; Wang TT
    EBioMedicine; 2015 Nov; 2(11):1600-6. PubMed ID: 26870784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. miR-216b enhances the efficacy of vemurafenib by targeting Beclin-1, UVRAG and ATG5 in melanoma.
    Luo M; Wu L; Zhang K; Wang H; Wu S; O'Connell D; Gao T; Zhong H; Yang Y
    Cell Signal; 2018 Jan; 42():30-43. PubMed ID: 28982601
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EPHA2 is a mediator of vemurafenib resistance and a novel therapeutic target in melanoma.
    Miao B; Ji Z; Tan L; Taylor M; Zhang J; Choi HG; Frederick DT; Kumar R; Wargo JA; Flaherty KT; Gray NS; Tsao H
    Cancer Discov; 2015 Mar; 5(3):274-87. PubMed ID: 25542448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simultaneous blocking of the pan-RAF and S100B pathways as a synergistic therapeutic strategy against malignant melanoma.
    Wu KJ; Ho SH; Wu C; Wang HD; Ma DL; Leung CH
    J Cell Mol Med; 2021 Feb; 25(4):1972-1981. PubMed ID: 33377602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells.
    Jenkins MH; Croteau W; Mullins DW; Brinckerhoff CE
    Matrix Biol; 2015 Oct; 48():66-77. PubMed ID: 25989506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.